therapeuticEstablished
Monoclonal antibody potency
Glycoengineered, afucosylated antibodies show enhanced cytotoxic activity and are used clinically to improve efficacy.1
Glycome Atlas
Loading reviewed Atlas content…
Glycome Atlas
process
Also known as antibody glycosylation, Fc glycosylation, mAb glycoengineering
GlcNAc (β1-N) → Asn; Fuc (α1-6) → GlcNAc; GlcNAc (β1-4) → GlcNAc; Man (β1-4) → GlcNAc; Man (α1-3) → Man; Man (α1-6) → Man; GlcNAc (β1-2) → Man; GlcNAc (β1-2) → Man
How to read these diagrams (SNFG)
Each shape is a class of sugar and each colour a specific one. Structures read right to left, with the reducing end (the point of attachment) on the right.
Plain-language answer
Therapeutic antibodies carry a small sugar group on a fixed spot of their tail region. This sugar is not decoration; it controls how well the antibody recruits immune cells to destroy a target such as a tumor cell.1
Because the sugar tunes potency and safety, drug makers deliberately engineer it. Small changes, like removing one fucose sugar, can substantially increase how effectively an antibody kills target cells.1
Technical detail
The conserved Asn297 Fc N-glycan of IgG governs Fc-gamma receptor and complement engagement; controlling features such as fucosylation, galactosylation, and sialylation lets biomanufacturers tune effector function and consistency.12
The biantennary Fc glycan modulates the conformation of the Fc region and its affinity for Fc-gamma receptors; afucosylated glycoforms markedly enhance antibody-dependent cellular cytotoxicity.1
Because glycosylation depends on the host cell line and process conditions, Fc glycans are treated as critical quality attributes and are engineered and monitored across production.1
Human relevance
Glycoengineered, afucosylated antibodies show enhanced cytotoxic activity and are used clinically to improve efficacy.1
Continue exploring
References